Valproic acid and HIV eradication—many questions remain

Although the amount of HIV in resting CD4+ cells clearly decreased when an intensive regimen of HAART and valproic acid was used, researchers are concerned that their laboratory equipment and techniques may not be sensitive enough to detect very low levels of latently infected cells. However, as interest in eradication studies grows, it is likely that HIV detection technologies and techniques will improve. This work will be time-consuming and labour-intensive, particularly because it involves assessing millions of cells.

Here are some issues that need to be explored in future eradication studies.

**Time**

Future studies will need to be longer. Already researchers are planning studies that last at least one year in the hope that this will improve the chances of eradication.

**Intensification**

Is the use of T-20 helpful? Researchers are not certain about the need for including this drug in eradication protocols. In the present study, two participants had “persistent, low levels of [HIV]” despite the use of T-20, according to the research team. To resolve this issue, future eradication studies may need a comparison group, where one receives T-20 and another does not. T-20 must be injected twice daily. But recent Canadian research suggests that a gas-powered needle-free delivery system (Biojector 2000) is as effective as the injections. No matter what method is used to deliver the drug, participants will have to be highly motivated and adherent. Future studies may also use different anti-HIV agents. For instance, boosted protease inhibitors such as lopinavir + ritonavir (Kaletra) and atazanavir (Reyataz) + ritonavir are candidates for this.

**The measure of success**

A major question for both scientists and PHAs is, “How will success in HIV eradication protocols be measured?” To answer this, at some point after the course of an eradication study, participants will have to stop using HAART. Levels of HIV antibodies, viral proteins and RNA (viral load) will be tracked at subsequent time points. There is some debate about the sensitivity of currently available technology and laboratory techniques to detect HIV when it is at very low levels.

For instance, two different teams of researchers, one in the United States and the other in the Netherlands, have found very low levels of HIV in men who have engaged in unprotected intercourse. Using readily available tests, these men did not have antibodies to HIV or any obvious traces of the virus in their blood. However, intensive and time-consuming lab investigation did find HIV in resting CD4+ cells. The implications of these findings need further exploration, but they suggest that HIV can hide quietly within cells.

**Will toxicity occur?**

Because valproic acid has the potential to interact with AZT, future eradication protocols may not use this nuke. This leaves the following options:

- 3TC
- FTC (available in the U.S. and E.U.)
- ddI
- d4T
Both “d” drugs—ddI and d4T—can cause pancreatitis and nerve damage and may be toxic to the liver. Also, d4T is associated with the loss of fat (lipoatrophy) under the skin. In rare cases, valproic acid is associated with the development of pancreatitis. So combining the “d” drugs with valproic acid may require that participants be closely and frequently monitored so that doctors can detect this problem in its infancy.

Beyond valproic acidFuture studies of eradication may include the use of cytokines such as IL-7 (interleukin-7), which can help stimulate HIV out of hiding without also ramping up the immune response and making CD4+ cells more susceptible to infection. Most experiments with IL-7 in people have been halted because their immune systems produced antibodies that attacked this chemical messenger and neutralized its effect. So, attempts are underway to make artificial IL-7 more like the form found naturally in the human body and, therefore, hopefully less likely to provoke an immune response. The new formulation of IL-7 will not likely be available until late 2006 (J-P Routy MD, personal communication).

**HDAC-1 inhibitors**

Valproic acid is one inhibitor of the enzyme HDAC-1. But researchers in the United States and European Union are working on developing other potential inhibitors of this enzyme that may be more effective than valproic acid. These new HDAC-1 inhibitors may be tested in PHAs if valproic acid is found to be insufficient.

**Bone marrow transplants**

The bone marrow is rich in white blood cells and lymphocytes and, not surprisingly, serves as a reservoir for HIV. In the late 1980s, researchers tried to destroy the bone marrow of PHAs with intensive doses of chemotherapy and/or radiation, after pre-treatment with AZT. The destruction of the bone marrow and its HIV-infected cells would be followed by a bone marrow transplant to help kick-start that organ into producing healthy, HIV-free cells. Unfortunately, none of these studies cured HIV infection. Moreover, such regimens can be very difficult to tolerate.

In this century, with a choice of potent anti-HIV agents at their disposal, some scientists are beginning to reconsider the idea of bone marrow ablation once again.

**REFERENCES:**


Produced By:

555 Richmond Street West, Suite 505, Box 1104
Toronto, Ontario M5V 3B1 Canada
Phone: 416.203.7122
Toll-free: 1.800.263.1638
Fax: 416.203.8284
www.catie.ca
Charitable registration number: 13225 8740 RR

Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at: